Lymphoma & Myeloma Clinical Trials | MD Anderson Cancer Center

Lymphoma Clinical Trials

Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)

Previously Untreated

2024-0114 A phase 3, multicenter, randomized, open-label trial to evaluate the safety and efficacy of Epcoritamab + Rituximab and Lenalidomide (R^2 ) compared to chemoimmunotherapy in previously untreated follicular lymphoma (EPCORE FL-2).

2024-0385 Randomized Phase III Study of Mosunetuzumab Vs. Rituximab for Low Tumor Burden Follicular Lymphoma

2023-0063 Phase 2 trial of Obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma

2022-0938 A phase 1 study of JV-213 autologous CD79b-targeting chimeric antigen receptor T-cell therapy in adults with relapsed or refractory B cell lymphomas

2021-0816 An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

Previously Treated

2024-0243 A phase 2 trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma

2022-0394 A Phase lb, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy of Mosunetuzumab or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma

2022-0551 A phase 1/2, open-label study of Valemetostat in combination with Rituximab and Lenalidomide in relapsed or refractory Follicular Lymphoma

2022-0459 A phase II trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in patients with relapsed B-cell NHL

2019-1250 A Phase 2, Open-Label, Single-Arm, Multi Cohort, Multi-Center Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHLl)

Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)

2020-0686 A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell

2022-0602 An open-label, phase I study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combination with Obinutuzumab and in combination with Glofitmab following a pre-treatment dose of Obinutuzumab administered in participants with relapsed/refractory B-Cell non-Hodgkin's lymphoma

2022-0147 A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy

2021-1088 A multicenter, open-label feasibility and randomized phase II study of Daratumumab with dose-adjusted EPOCH in newly diagnosed Plasmablastic Lymphoma with or without HIV

2022-0918 Expanded access study for the treatment of patients with commercially out-of-specification Axicabtagene Ciloleucel

2023-0329 An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

2023-0031 Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma.

2023-0673 A phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as second-line therapy for relapsed or refractory patients with large B Cell Lymphoma

2023-0738 An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

2023-0942 A modular phase I/II, open-label, multicenter study to evaluate the safety, tolerability and efficacy of AZD3470, a PRMT5 inhibitor, as Monotherapy and in combination with Anti-cancer Agents in participants with relapsed/refractory Hematologic Malignancies. 2023-0864 A pilot study of Emapalumab for the treatment of CAR T-Cell therapy-associated prolonged cytopenia 2024-0115 A phase 3, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-COP to the CHOP regimen alone in newly diagnosed patients with peripheral t cell lymphoma. 2024-0431 A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3) 2024-0453 An open-label, dose escalation and dose expansion trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with relapsed or refractory primary central nervous system lymphoma 2024-0430 A phase 1 first in human study of ARV-393 in adult participants with advanced Non-Hodgkin's Lymphoma 2024-1146 A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and Safety of Golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell Lymphoma 2024-1534 A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed/refractory T-cell lymphoma (r/r TCL) 2024-1549 A modular phase I/II open-label dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a T cell-engaging antibody targeting CD20 in subjects with relapsed or refractory B-cell malignancies (TITANium) 2025-0344 A phase 2/3, open-label, single-arm, multicenter, historical control study to evaluate ELA026 in participants with secondary hemophagocytic lymphohistiocytosis (sHLH)

Mantle Cell Lymphoma

2022-0722 A single-Arm, open-label, multicenter phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory Mantle Cell Lymphoma

2023-0695 Tafasitamab, Lenalidomide and Venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)

2025-0068 A master protocol to evaluate the long-term safety of Pirtobrutinib

2023-0413 Phase II study of Pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients

2024-0220 GATE1: A multicenter phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma

2024-1726 Phase 1 trial of BTM-3566 in relapsed/refractory mature B Cell Lymphomas.

2025-0045 A phase 3 randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma

2012-1107 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Hodgkin Lymphoma

2021-0091 A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

T-Cell Lymphoma

Previously Treated

2023-0962 A phase 3, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor Soquelitinib versus physician's choice standard of care treatment (Selected Single Agent) in participants with Relapsed/Refractory peripheral T-cell Lymphoma not otherwise specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Untreated Peripheral T-Cell Lymphoma

2024-0517 A Phase II, Single-Center, Single-Arm Study Evaluating The Safety And Efficacy Of Golidocitinib In The Management Of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study)

Previously Treated Peripheral T-Cell Lymphoma

2022-0437 A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

2024-0198 A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies